MSCI中国非必需消费类股ETF-Global X CHIQ 深 沪
等待开盘 09-05 09:30:00 美东时间
22.39
-0.320
-1.41%
华盛通- 最 高22.455
- 今 开22.36
- 成交量 14.73万股
- 最 低 22.21
- 昨 收 22.71
- 总市值 2.41亿
- 52周最高 24.5025
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 15.7525
- 委 比 92.59%
- 总股本 1078.14万
- 历史最高 42.7968
- 量 比 1.79
- 振 幅 1.08%
- 历史最低 7.4651
- 每 手 1
- 风险率 1.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美FDA意外叫停一款基孔肯雅热疫苗 法国制药商股价崩跌超两成
①法国生物技术公司瓦尔内瓦欧股跌超20%，因美FDA暂停其基孔肯雅热疫苗IXCHIQ的使用，令市场意外； ②瓦尔内瓦正在对严重不良事件案例进行调查，并表示将继续向其他批准该疫苗的国家供应。今年上半年，IXCHIQ为公司带来了750万欧元的销售额。
08-25 19:23
Valneva Announces FDA Suspension Of IXCHIQ License In United States Following Four New Serious Adverse Events Reports
The suspension of the license is effective immediately and requires Valneva to stop shipping and selling of IXCHIQ® in the United States.
08-25 13:46
Valneva’s Chikungunya Vaccine IXCHIQ® Gains Health Canada Approval
Valneva ( ($VALN) ) has issued an announcement. On August 18, 2025, Valneva SE ...
08-18 22:07
Reborn Coffee Expands Globally, Eyes Blockchain For Future-Proof Financial Management
Reborn Coffee Inc. (NASDAQ: REBN) is reviewing blockchain-based digital asset strategies to strengthen its financial foundation, while expanding globally.
08-18 21:56
FDA Clears Valneva's IXCHIQ For Continued Use In Adults 60+ And Approves Updates To Prescribing Information
The FDA decision follows the announcement in July by the European Medicines Agency (EMA)1 which recommended the lifting of temporary restrictions in elderly people after the conclusion of a thorough review of
08-07 14:53
Valneva's Chikungunya Vaccine IXCHIQ Cleared By European Medicines Agency For Use In Seniors After Safety Committee Review
Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating people aged 65 years and above after
07-11 23:36
Valneva Partners With CSL Seqirus For Exclusive Marketing And Distribution Of Proprietary Vaccines In Germany, Beginning July 2025
Under the agreed terms, CSL Seqirus will start commercializing Valneva's single-dose chikungunya vaccine IXCHIQ from July 2025, and Valneva's Japanese Encephalitis vaccine IXIARO and cholera/ETEC1 vaccine DUKORAL from
06-26 13:35
Hyatt Targets Upscale Travelers Seeking Locally Rooted Stays With New Brand
Hyatt introduces Unscripted, a new brand targeting upscale travelers with locally rooted experiences. Its expansion strategy leads to financial growth.
05-31 00:52
Valneva's IXCHIQ Use In Elderly Paused By FDA And CDC Amid Ongoing Review Of Serious Adverse Events
This update follows an earlier recommendation from the U.S. Advisory Committee on Immunization Practices (ACIP) to include a precaution related to the use of IXCHIQ® in persons aged 65 and over and a similar
05-12 14:19
Breaking Down Valneva: 6 Analysts Share Their Views
During the last three months, 6 analysts shared their evaluations of Valneva (N...
03-21 20:01
